Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High - Time to Buy?

Key Points

• Theravance Biopharma (NASDAQ: TBPH) reached a new 52-week high of $14.93 during trading, with the last price noted at $14.86.
• Analysts maintain a consensus rating of "Buy" for the stock, with a price target averaging $23.00, while some recent ratings range from "Hold" to "Strong Buy."
• Institutional investors hold 99.10% of the company's stock, with notable increases in stakes from several hedge funds in recent quarters.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $14.93 and last traded at $14.86, with a volume of 40238 shares traded. The stock had previously closed at $14.41.

Analyst Ratings Changes

Several equities analysts recently issued reports on TBPH shares. B. Riley assumed coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a "buy" rating and a $28.00 price target on the stock. BTIG Research upped their target price on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Weiss Ratings restated a "hold (c)" rating on shares of Theravance Biopharma in a research report on Saturday, September 27th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. Finally, Zacks Research cut shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Monday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $23.00.

Theravance Biopharma Stock Up 3.1%

The company has a market cap of $748.10 million, a P/E ratio of 62.15 and a beta of -0.03. The business has a fifty day simple moving average of $13.24 and a two-hundred day simple moving average of $11.12.

Insider Activity

In related news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. GAMMA Investing LLC raised its stake in shares of Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 3,281 shares during the period. Tower Research Capital LLC TRC raised its stake in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after acquiring an additional 781 shares during the period. AQR Capital Management LLC purchased a new position in Theravance Biopharma during the first quarter valued at approximately $101,000. R Squared Ltd boosted its position in shares of Theravance Biopharma by 636.6% in the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 10,822 shares during the period. Finally, Tabor Asset Management LP purchased a new stake in shares of Theravance Biopharma in the first quarter worth $135,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.